There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
Athens General Hospital "G. Gennimatas"
Athens, Attica, Greece
Myocardial damage marker levels
Time frame: Days 1-2 post-CABG
All cause mortality
Time frame: At one and at six months after CABG
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.